ID: ALA3409336

Max Phase: Preclinical

Molecular Formula: C21H25N5O6S

Molecular Weight: 475.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc2[nH]cc(CCCCCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)c2c(=O)[nH]1

Standard InChI:  InChI=1S/C21H25N5O6S/c22-21-25-17-16(19(30)26-21)11(10-23-17)4-2-1-3-5-12-6-8-14(33-12)18(29)24-13(20(31)32)7-9-15(27)28/h6,8,10,13H,1-5,7,9H2,(H,24,29)(H,27,28)(H,31,32)(H4,22,23,25,26,30)/t13-/m0/s1

Standard InChI Key:  ARIQPXNXGFKWNW-ZDUSSCGKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 475.53

Molecular Weight (Monoisotopic): 475.1526

AlogP: 1.90

#Rotatable Bonds: 12

Polar Surface Area: 191.26

Molecular Species: ACID

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.63

CX Basic pKa: 4.86

CX LogP: 1.38

CX LogD: -3.70

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.21

Np Likeness Score: -0.28

References

1. Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A..  (2015)  Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.,  58  (3): [PMID:25602637] [10.1021/jm501787c]

Source

Source(1):

• Scientific Literature